- Home
- MBRX vs QNRX Comparison
MBRX vs QNRX Comparison
Compare MBRX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- QNRX
- Stock Information
- Founded
- MBRX 2015
- QNRX 2018
- Country
- MBRX United States
- QNRX United States
- Employees
- MBRX N/A
- QNRX N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- MBRX Health Care
- QNRX Health Care
- Exchange
- MBRX Nasdaq
- QNRX Nasdaq
- Market Cap
- MBRX 5.7M
- QNRX 5.3M
- IPO Year
- MBRX 2016
- QNRX N/A
- Fundamental
- Price
- MBRX $1.88
- QNRX $0.57
- Analyst Decision
- MBRX Strong Buy
- QNRX Strong Buy
- Analyst Count
- MBRX 2
- QNRX 1
- Target Price
- MBRX $24.00
- QNRX $4.00
- AVG Volume (30 Days)
- MBRX 62.3K
- QNRX 1.4M
- Earning Date
- MBRX 11-08-2024
- QNRX 03-12-2025
- Dividend Yield
- MBRX N/A
- QNRX N/A
- EPS Growth
- MBRX N/A
- QNRX N/A
- EPS
- MBRX N/A
- QNRX N/A
- Revenue
- MBRX N/A
- QNRX N/A
- Revenue This Year
- MBRX N/A
- QNRX N/A
- Revenue Next Year
- MBRX N/A
- QNRX N/A
- P/E Ratio
- MBRX N/A
- QNRX N/A
- Revenue Growth
- MBRX N/A
- QNRX N/A
- 52 Week Low
- MBRX $0.40
- QNRX $0.43
- 52 Week High
- MBRX $6.24
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- MBRX 47.84
- QNRX 43.80
- Support Level
- MBRX $1.65
- QNRX $0.56
- Resistance Level
- MBRX $1.99
- QNRX $0.63
- Average True Range (ATR)
- MBRX 0.20
- QNRX 0.07
- MACD
- MBRX 0.04
- QNRX -0.00
- Stochastic Oscillator
- MBRX 71.79
- QNRX 11.56
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.